WallStSmart

Abbott Laboratories (ABT)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1153249% more annual revenue ($45.13B vs $3.91M). ABT leads profitability with a 13.9% profit margin vs -296.8%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

INBS

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -14.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-22.7%)

Margin of Safety

-22.7%

Fair Value

$70.88

Current Price

$85.60

$14.72 premium

UndervaluedFair: $70.88Overvalued
INBSSignificantly Overvalued (-23.2%)

Margin of Safety

-23.2%

Fair Value

$4.26

Current Price

$2.44

$1.82 premium

UndervaluedFair: $4.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

INBS3 strengths · Avg: 9.7/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
45.5%10/10

Revenue surging 45.5% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.77M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-170.2%2/10

ROE of -170.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.24 — expect wider price swings.

INBS is growing revenue faster at 45.5% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.

Want to dig deeper into these stocks?